GTBPGT Biopharma, Inc.

Nasdaq gtbiopharma.com


$ 2.81 $ 0.01 (0.35 %)    

Friday, 28-Jun-2024 13:40:24 EDT
QQQ $ 479.98 $ -2.50 (-0.52 %)
DIA $ 391.11 $ -0.43 (-0.11 %)
SPY $ 544.70 $ -2.15 (-0.39 %)
TLT $ 91.77 $ -1.74 (-1.86 %)
GLD $ 215.03 $ 0.02 (0.01 %)
$ 2.83
$ 2.66
$ 0.00 x 0
$ 0.00 x 0
$ 2.66 - $ 2.81
$ 2.60 - $ 10.95
54,333
na
3.91M
$ 0.33
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-15-2024 03-31-2024 10-Q
2 03-26-2024 12-31-2023 10-K
3 11-01-2023 09-30-2023 10-Q
4 08-07-2023 06-30-2023 10-Q
5 05-15-2023 03-31-2023 10-Q
6 03-30-2023 12-31-2022 10-K
7 10-31-2022 09-30-2022 10-Q
8 08-15-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 03-28-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-23-2021 06-30-2021 10-Q
13 05-17-2021 03-31-2021 10-Q
14 04-16-2021 12-31-2020 10-K
15 11-13-2020 09-30-2020 10-Q
16 08-14-2020 06-30-2020 10-Q
17 05-15-2020 03-31-2020 10-Q
18 03-27-2020 12-31-2019 10-K
19 11-14-2019 09-30-2019 10-Q
20 08-14-2019 06-30-2019 10-Q
21 05-15-2019 03-31-2019 10-Q
22 03-29-2019 12-31-2018 10-K
23 11-14-2018 09-30-2018 10-Q
24 08-14-2018 06-30-2018 10-Q
25 05-15-2018 03-31-2018 10-Q
26 03-01-2018 12-31-2017 10-K
27 11-14-2017 09-30-2017 10-Q
28 08-11-2017 06-30-2017 10-Q
29 04-28-2017 03-31-2017 10-Q
30 03-31-2017 12-31-2016 10-K
31 11-14-2016 09-30-2016 10-Q
32 08-10-2016 06-30-2016 10-Q
33 05-13-2016 03-31-2016 10-Q
34 03-30-2016 12-31-2015 10-K
35 11-13-2015 09-30-2015 10-Q
36 08-14-2015 06-30-2015 10-Q
37 05-14-2015 03-31-2015 10-Q
38 03-31-2015 12-31-2014 10-K
39 01-08-2015 12-31-2013 10-K
40 01-08-2015 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 gt-biopharma-announces-fda-clearance-for-gtb-3650-ind-application-phase-1-trial-to-begin-in-h2-2024-with-initial-data-expected-in-h1-2025

GTB-3650 Phase 1 trial initiation expected in H2 2024; initial clinical data expected in H1 2025GTB-5550 TriKE® IND submission ...

 whats-going-on-with-gt-biopharma-stock-tuesday

GT Biopharma entered into a definitive securities purchase agreement for the purchase and sale of 740,000 shares of its common ...

 gt-biopharma-shares-resume-trade
GT Biopharma Shares Resume Trade
05/21/2024 13:39:14

 whats-going-on-with-gt-biopharma-stock

GT Biopharma shares are moving on heavy trading volume despite a lack of company-specific news. The stock is one of the top tre...

 gt-biopharma-shares-resume-trade
GT Biopharma Shares Resume Trade
05/20/2024 13:53:48

 gt-biopharma-q1-eps-164-beats-270-estimate

GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(1.64) per share which beat the analyst consensus estimate of $(2.70) ...